NewAmsterdam Pharma Company N.V. (NAMS)

Market Cap	4.09B +81.5%
Revenue (ttm)	22.50M -50.6%
Net Income	-203.82M
EPS	-1.72
Shares Out	114.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	796,235
Open	34.38
Previous Close	34.63
Day's Range	34.00 - 36.00
52-Week Range	14.06 - 42.00
Beta	0.07
Analysts	Strong Buy
Price Target	47.33 (+33.02%)
Earnings Date	Feb 18, 2026

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 77
• Stock Exchange: NASDAQ
• Ticker Symbol: NAMS
• Website: https://www.newamsterdampharma.com

Financial Performance

In 2025, NAMS's revenue was $22.50 million, a decrease of -50.61% compared to the previous year's $45.56 million. Losses were -$203.82 million, -15.64% less than in 2024.

Analyst Summary

According to 9 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price target is $47.33, which is an increase of 33.02% from the latest price.

Price Target

$47.33

(33.02% upside)

Analyst Consensus: Strong Buy